Journal List > J Korean Diabetes > v.14(1) > 1054894

TOOLS
Noh: Glycemic Control in Diabetic Patients with Diabetic Nephropathy
Focused Issue

J Korean Diabetes 2013;14(1):23-26.

Published online: 7 January 2013

DOI: https://doi.org/10.4093/jkd.2013.14.1.23

Glycemic Control in Diabetic Patients with Diabetic Nephropathy

Junghyun Noh

Department of Internal Medicine, Inje University College of Medicine, Goyang, Korea

교신저자: 윤지성, 대구광역시 남구 대명동 317-1 영남대학교 의료원 내분비대사내과, E-mail: jhnoh@paik.ac.kr

Copyright © 2013 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Diabetes mellitus is a leading cause of kidney disease; nearly one-third of patients with diabetes develop nephropathy. Several trials assessed the effect of intensive glycemic control in diabetic patients and provided strong evidence that intensive therapy reduces the incidence and progression of diabetic nephropathy, especially microalbuminuria, an early marker of diabetic nephropathy. The presence of impaired kidney function should influence selection, dosing, and monitoring of hypoglycemic agents. This article reviews the effects of intensive glycemic control on the development and progression of diabetic nephropathy and the clinical use of antidiabetic therapies in patients with chronic kidney disease.

Keywords: Glycemic control, Diabetic nephropathy

REFERENCES

1. SDCCT group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977–86.
2. SStratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405–12.
3. SADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560–72.
4. SIsmail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I. ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010; 376:419–30.
5. SDuckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360:129–39.
crossref
6. SOhkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shicgiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insuin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28:103–17.
7. SKalantar-Zadeh K, Kopple JD, Regidor DL, Jing J, Shinaberger CS, Aronovitz J, McAllister CJ, Whellan D, Sharma K. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007; 30:1049–55.
8. SCharpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000; 26(Suppl. 4):73–85.
9. SLubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. AmJ Kidney Dis. 2007; 50:865–79.
10. SReilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial. 2010; 23:163–8.
11. SHasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with andwithout impaired renal function. Diabetes Care. 2003; 26:886–91.
12. SInoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, Takamitsu Y. Pharmacokinetics of nateglinide and itsmetabolites in subjects with type 2 diabetesmellitus and renal failure. Clin Nephrol. 2003; 60:90–5.
13. SBergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007; 30:1862–4.
14. SBristol-Myers Squibb. Onglyza (saxagliptin) [Internet]. New York: Bristol-Myers Squibb Company;c1999-2007. [cited 2009 Sep 11]. Available from. http://packageinserts.bms.com/pi/pi_onglyza.pdf.
15. SH e YL. Clinicalpharma cokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012; 51:147–62.
16. SMikhail N. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease. Postgrad Med. 2012; 124:138–44.
17. SLinnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007; 64:317–27.
crossref
18. SBuse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374:39–47.
19. SLipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011; 34:1431–7.
TOOLS
Similar articles